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Abstract
Background: As an important stress-response mechanism, autophagy plays crucial role in the tumor formation and
drug resistance of cancer cells including osteosarcoma (OS). OS cancer stem cells (CSCs) also are considered a key
factor of tumorigenesis, drug resistance and tumor recurrence. However, the relationship between autophagy and
OS CSCs still remains unclear.
Methods: CD271+ OS CSCs and CD271- OS cells were isolated by magnetic activated cell sorting. The autophagy
level was evaluated by the mRNA expression of autophagy genes, the protein level of LC3II and p62, and the mean
number of GFP-LC3 dot per cell. Lentivirus-delivered specific shRNA was utilized to inhibit the corresponding gene
expression. The cell viability was examined with CCK8 assay. The cell proliferation level was detected with BrdU
staining assay. Cell death was determined by Annexin V/PI double staining of fluorescence activated cell sorting,
lactate dehydrogenase release and caspase-3 activity. Tumorigenicity ability was evaluated by colony and sphere
formation assay, the protein expression of stemness markers and tumor formation in nude mice.
Results: Our data indicated that CD271+ OS CSCs had a similar basic autophagy level with CD271- OS cells.
Autophagy deficiency had no observable effects on the levels of cell proliferation and death both in CD271+ and
CD271- OS cells under normal condition. However, CD271+ OS cells showed a higher autophagy activity than
CD271- OS cells under hypoxia and low nutrient (LH) condition. Moreover, autophagy-deficient CD271+ OS cells
lost the advantage of tolerance to LH condition compared to CD271- OS cells. Meanwhile, autophagy deficiency
enhanced the sensitivity to chemotherapeutics in the CD271+ cells to the comparable level in the CD271- cells.
More importantly, deficient-autophagy decreased the protein expression of stemness markers and caused the
disappearance of the superiority in tumorigenicity in vitro and vivo in CD271+ OS cells.
Conclusion: The results above demonstrated that autophagy contributes to the stem-like features of CD271+ OS
CSCs. Inhibition of autophagy is a promising strategy in the CSCs-targeting OS therapy.
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Background
Osteosarcoma (OS) is one of the most common primary
malignant bone tumors and mainly affects children, ado-
lescents, and young adults (between the ages of 10 to
25) [1]. OS often occurs in long bones, including the dis-
tal femur, proximal tibia and humerus [2]. he current
therapy strategy for OS consists of the addition of
chemotherapy after surgical removal of tumor, and neo-
adjuvant chemotherapy followed by surgery. Although
combinational chemotherapy has been improved, the
five-year survival rate for OS patients still is about 70%
[3]. Therefore, novel therapeutic strategy for enhancing
the chemotherapy sensitivity of the OS has yet to be
explored.
Cancer stem cells (CSCs) are seen as a subpopulation
of self-renewing tumor cells, which can differentiate into
the daughter tumor cells, have the lower sensitivity to
chemotherapy and radiotherapy, and exhibit tumor re-
initiating property. Thus, CSCs are deemed to a promis-
ing target for cancer therapy. Diverse studies report that
OS also has CSCs [4]. For instance, CD133 + [5–7],
CD117 + Stro-1 + [8] and Sca-1 + [9] populations in OS
cells revealed the CSCs-like characteristics. CD271, an
MSC antigen, was likewise identified as an effective
OS-CSCs marker. CD271+ cells showed many stem-like
features including self-renew, the advantage of forming
sarcospheres, drug resistance and tumorigenicity [10].
Macroautophagy (hereafter termed autophagy) is a
conserved self-digestive process that serves as a
lysosome-dependent degradation and recycling mechan-
ism for providing the biological materials of biosynthesis
and energy synthesis. Under stresses, autophagy plays an
important role in eliminating redundant or damaged
macromolecules, such as proteins, lipids and organelles.
Many studies suggest that autophagy contributes to the
resistance of tumor cells to sterile microenvironment
and chemotherapy [11].
Numerous reports demonstrate that autophagy supports
the stemness of CSCs in some types of tumors, including
breast cancer [12–14], pancreatic ductal adenocarcinoma
[15, 16], colon cancer [17, 18], hepatocarcinoma [19] and
bladder cancer [20]. On the other hand, various researches
also reveal that under some conditions, CSCs have a lower
autophagy level than non-CSCs [21–23]. Meanwhile, Yujie
Fu and his colleagues indicated that autophagy contrib-
uted to the resveratrol-induced decrease of CSCs in
breast cancer [24]. Liu S, et al. also reported that inhib-
ition of autophagy rescued the reduction of CSCs
induced by Ginsenoside rh2 treatment [25]. These re-
searches showed the complexity of the roles of autoph-
agy in CSCs. Thus, in this study, we investigated the
influence of autophagy on OS CSCs by detecting




The SAOS2 and MNNG/HOS human OS cell lines were
obtained from the American Type Culture Collection
and Cell Bank of Chinese Academy of Sciences, respect-
ively. SAOS2 cells were cultured in McCoy’s 5A medium
(GIBCO, Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS, GIBCO). MNNG/HOS
cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO) supplemented with 10% FBS.
All cells were grown in 37 °C under humidified air con-
taining 5% CO2.
Low nutrients medium (glucose 100 mg/L, no L-
glutamine) was mixed by low glucose DMEM (GIBCO,
No. 11880036) and no glucose DMEM (GIBCO, No.
A14430-01) at the ratio of 1:9. For hypoxia condition,
cells were cultured in a tri-gas incubator (SANYO,
Osaka, Japan) maintained at 1% O2, 94% N2 and 5% CO2.
The low nutrients and hypoxia (LH)-treated cells were
cultured in normal condition for overnight, and were cul-
tured under LH condition for the indicated times.
Magnetic activated cell sorting (MACS)
CD271+ and CD271- OS cells were sorted using CD271
MicoBead Kit (Order no. 130-092-819, Miltenyi Biotec.
Auburn, CA) depending on its manual. Briefly, OS cells
were collected and dissociated into single-cell suspen-
sion with MACS separation Buffer. OS cells were incu-
bated with FcR Blocking Reagent and CD271-PE
antibody in 4 °C for 10 min. Then, FcR Blocking Reagent
and Anti-PE MicroBeads were added and mixed at 4 °C
for 15 min. After washed with PBS, CD271+ OS cells
were sorted with magnetic separation columns and
MACS separator. The quality of MACS was checked
with flow cytometry (Order no.130-110-115, Miltenyi
Biotec.) on a BD Fluorescence Activated Cell Sorting
(FACS) Calibur machine (BD Biosciences, San Jose, CA).
FACS
The indicated OS cells were dissociated into single-cell
suspension. 105 cells/sample was added with VioBright
FITC-labeled CD271 antibody (Order no.130-110-115,
Miltenyi Biotec.) or corresponding isotype controls and
were incubated in 4 °C for 30 min. After washed twice
with PBS, these cells were analyzed with a BD FACS
Calibur machine (BD Biosciences).
Quantitative real-time polymerase chain reaction (qPCR)
Total RNA was extracted from the indicated OS cells
using an Ultra-Pure Total RNA QuickExtract Kit (BioTeke
corporation, Beijing, China) according to its protocol.
RNA concentrations were quantified with a ND-2000
spectrophotometer (Nanodrop Technologies, Thermo
Scientific, Wilmington, DE). Then, RNA was reverse
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transcribed with a RT Reagent Kit (TaKaRa, Tokyo, Japan)
to generate complementary DNA. The qPCR was per-
formed in a Roche LightCycler® 480 System utilizing
regular 2-step qPCR program. The specific primers
were purchased from QIAGEN: Beclin1, Product no.
PPH05670B; LC3B, Product no. PPH17765B; Atg5,
Product no. PPH07779A; Atg7, Product no. PPH15687C;
GAPDH, Product no. PPH00150F. The relative mRNA ex-
pressions of the indicated genes were calculated using the
ΔΔCt method, and GAPDH was used for normalization.
Western blot
The indicated OS cells were harvested and lysed in pro-
tein extraction reagent (Pierce, Thermo Scientific) with
cocktail (Roche Life Science, Indianapolis, IN). Samples
containing equal amounts of protein were subjected to
SDS-PAGE. The blots were incubated with the primary
antibodies against LC3, SQSTM1/p62, Atg5, Atg7,
Nanog, Oct4, Stat3, p-Stat3 (all from Cell Signaling
Technology, Beverly, MA), GAPDH and β-actin (both
from Hangzhou HuaAn Biotech, Hangzhou, Zhejiang,
China), and then with the secondary antibodies labeled
peroxidase (Hangzhou HuaAn Biotech) and chemilu-
minescent substrates. GAPDH and β-actin served as
control proteins.
GFP-LC3 transfection
The GFP-LC3-carrying adenovirus (Hanbio, Shanghai,
China) was used to transfected the indicated OS cells
according to the manufacturer’s protocol. After the indi-
cated treatments, autophagy level was examined with
counting the number of GFP-LC3 punta per cells under
a fluorescence microscope (Olympus IX73, Melville,
NY). A minimum of 100 cells per sample was calculated
in three replicates for each experiment.
Short hairpin RNA (shRNA)-mediated gene silencing
The indicated OS cells were transfected with lentivirus
vector expressing Atg5-shRNA (5’-G ATTCATGGAAT
TGAGCCAAT-3’), Atg7-shRNA (5’-CCAGAGAGTT-
TACCTCTCATT-3’) or scramble (Scr)-shRNA (5’-
TTCTCCGAACGTGTCACGT-3’) (all from Shanghai
GeneChem, Shanghai, China). After 2 days, the trans-
fected cells were selected by puromycin (2 mg/ml,
Sigma, St. Louis, Mo) for 48 h.
Cell Counting kit-8 (CCK8) assay
The cell viability was detected with CCK8 assay (Beyo-
time Institute of Biotechnology, Suzhou, Jiangsu, China).
After the indicated treatments, CCK8 solution (10 μl)
was added in each well (96-well plates). Then, the indi-
cated OS cells were cultured at 37 °C for another 1 h.
The optical density of each well was measured at
450 nm with a Bio-Tek microplate reader (Bio-Tek
Instruments, Thermo Fisher Scientific, Winooski, VT).
5-Bromo-2-deoxyUridine (BrdU) staining
BrdU (10 μM, Sigma) was added to the culture media of
the indicated OS cells. After 24 h, the cells were fixed in
4% paraformaldehyde for 10 mins, and permeabilized in
0.1% Triton X-100 for 5 mins at room temperature.
DNA of these cells was denatured by HCl (2 M) for 20
mins at 37 °C. Then, these cells were neutralized by borate
buffer (0.1 M, pH 8.5) for 5 mins three times. BrdU was
detected by anti-BrdU IgG1 conjugated to Alexa Fluor
555 (Invitrogen), and nuclei were stained with DAPI.
Detection of cell death by Annexin V/PI double staining
After the indicated treatments, cells were stained by FITC-
labeled Annexin V and PI (Nanjing Keygen Biotech,
Nanjing, Jiangsu, China) depending to its protocol. FACS
analysis for Annexin V/PI double staining was done with a
BD FACS Calibur machine (BD Biosciences). Dead cells
consisted of PI+ cells (Q1), PI + FITC+ cells (Q2) and FITC
+ cells (Q4). All experiments were carried out three times.
Colony formation assay
The indicated cells were seeded in McCoy’s 5A or
DMEM with 1% FBS at a density of 400 cells/well on 6-
well plates. After 10 days, these plates were stained with
crystal violet (Beyotime Institute of Biotechnology) and
counted the number of colonies per well. All experi-
ments were performed three times.
Tumor sphere formation assay
The indicated cells were seeded in McCoy’s 5A or
DMEM with 10 ng/ml bFGF, 20 ng/ml EGF and 2% B27
(Invitrogen) at a density of 1000 cells/well on ultra low
attachment 6-well plates. Fresh equal amount of bFGF
and EGF were added every 2 days. After 10 days, the
number of tumor spheres containing at least 50 cells per
well was observed and counted by a microscopy.
Tumor formation in vivo
Male BALB/c nude mice (6 weeks old, weighing 18–20 g)
were purchased from Shanghai Experimental Center,
Chinese Science Academy, Shanghai. The mice were kept
at a specific pathogen-free animal facility. All procedures
of animal treatments followed the guidelines issued by
National Institute of Health and this study was approved
by the Animal Ethics Committee of Shanghai University
of Traditional Chinese Medicine (TCM-2015-018-E20).
The indicated cells of different numbers were sus-
pended in McCoy’s 5A or DMEM with an equal volume
(100 μl) of Matrigel (BD Biosciences) and injected sub-
cutaneously into the oxter of left forelimb of BALB/c
nude mice. In the Chloroquine (CQ, sigma) combination
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groups, the mice were received intraperitoneal injection
of autophagy inhibitor CQ (60 mg/kg) once every three
days. The volume of subcutaneous tumors in mice was
monitored once a week for 6 weeks. The tumors were
measured with electronic calipers and tumor volume
was estimated using the formula 1/2*a*b2, where ‘a’ and
‘b’ were the longest and shortest diameters of the tumor,
respectively. After 6 weeks, the mice that had a tumor
(diameters ≥ 3 mm) were considered the tumor-bearing
mice. And the number of tumor-bearing mice of every
group was counted. The tumors were soaked in 10%
neutral-buffered formalin for paraffin embedding and
subsequent hematoxylin and eosin (H&E) staining.
Detection of lactate dehydrogenase (LDH) release
The LDH release was quantified with a LDH Cytotox-
icity Detection Kit (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’s protocol.
After the indicated treatments, 100 μl of reaction cock-
tail was added to 100 μL of culture medium and was in-
cubated for 30 mins at room temperature. Then, the
LDH release was tested by measuring the absorbance at
490 nm with a Bio-Tek microplate reader (Bio-Tek In-
struments). The value of LDH release was established
with the following formula: LDH release = (exp. value -
low control)/(high control - low control). All treatment
conditions were performed in six replicate and all exper-
iments were repeated three times.
Detection of caspase-3 activity
The caspase-3 activity was quantified with an APOP-
CYTO Caspase-3 Colorimetric Assay Kit (MBL Inter-
national Corp., Nagoya, Japan) according to the
manufacturer’s instruction. In brief, the indicated cells
were harvested and lysed. Cell lysate (20 μl) was added
to the buffer containing Ac-DEVD-pNA to yield a
100 μl total reaction volume, and the mixture was incu-
bated for 1 h at 37 °C. Optical density of each well was
evaluated at 405 nm using a Bio-Tek microplate reader
(Bio-Tek Instruments). The concentrations of released
pNA were quantified based on the absorbance and cali-
bration curve. The caspase-3 activity in the control
group is deemed as 1.
Drug sensitivity assessment
The indicated cells were seeded in 96-well plates at a
density of 5000 cells/well. After overnight, cells were
treated with Cisplatin or Epirubicin at different concen-
trations (Cisplatin, 0–8 μg/ml; Epirubicin, 0–5 μg/ml)
for 48 h. The cell viability was assessed with CCK8 assay
to determine the IC50 value.
Statistics
Data are shown as the means ± S.D. Statistical signifi-
cance was determined with One-way ANOVA using
GraphPad Prism 6.04 software. For all tests, A value of
P < 0.05 was considered statistically significant.
Results
CD271+ OS cells have higher autophagy ability rather
than basic autophagy level compared to CD271- OS cells
To study the role of autophagy in OS CSCs, we isolated
CD271+ OS cells and CD271- OS cells with MACS and ex-
amined their purities with FACS (Fig. 1a). Then, we ex-
plored whether there is the difference in autophagy level
between CD271+ and CD271- OS cells. Firstly, we detected
the basic mRNA expression of various autophagy-essential
genes, including Beclin1, LC3B, Atg5 and Atg7. However,
only the basic mRNA expression of LC3B showed a higher
level in CD271+ OS cells opposed to that in CD271- OS
cells (Fig. 1b). We further examined the mRNA expression
of these genes in CD271+ and CD271- OS cells after au-
tophagy inducer treatment. Both nutrient deficiency and
hypoxia are the classical features of tumor microenviron-
ment, and can induce autophagy [11]. The results revealed
that the mRNA expression of all four genes in CD271+ OS
cells had a higher level than those of CD271- OS cells after
LH treatment (Fig. 1b). Western blot assay showed similar
results. After LH treatment, CD271+ OS cells showed
higher LC3II level and lower p62 level compared to
CD271- OS cells (Fig. 1c). Moreover, LC3 dots, an indicator
of autophagosome formation, also had a higher number in
CD271+ OS cells than that in CD271- OS cells under LH
condition (Fig. 1d). These data demonstrated that although
there is no significant difference in the basic autophagy
level between CD271+ OS CSCs and CD271- OS cells,
CD271+ OS CSCs have higher autophagy activity than
CD271- OS cells under LH condition.
The basic biological activities in both CD271+ and CD271-
OS cells are not significantly affected by autophagy
deficiency under normal condition
OS CSCs had various stem-like features, such as the resis-
tances to ischemic microenvironment and chemotherapeu-
tics, and high tumorigenicity in vitro and vivo [4]. We need
to confirm the influences of autophagy deficiency on the
basic biological activities in OS CSCs and OS non-CSCs be-
fore evaluating the impacts of autophagy deficiency on
these stemness features of OS CSCs. Thus, we used specific
shRNA to disturb expression of Atg5 or Atg7 in SaoS2 OS
cells (Fig. 2a), and investigate the impact of autophagy in-
hibition on the basic biological activity of SaoS2 cells under
normal condition. FACS analysis exhibited that inhibition
of autophagy did not result in the remarkable change of the
percentage of CD271+ cells in SaoS2 cells (Fig. 2b). CCK8
assay also showed that autophagy deficiency had no
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significant influence on cell viability both in CD271+ and
CD271- SaoS2 cells (Fig. 2c). The results of BrdU staining
and Annexin V/PI double staining further suggested that
autophagy deficiency had no obvious influences on cell pro-
liferation and death both in CD271+ and CD271- SaoS2
cells (Fig. 2d and e). Moreover, these detections in MNNG/
HOS OS cells also obtained similar results (Fig. 2f–i). These
data demonstrated that autophagy deficiency had no prom-
inent impacts on the basic biological activities both in
CD271+ and CD271- OS cells.
Autophagy-deficient CD271+ OS cells lose the advantage
of tolerance to LH condition
Numerous studies have reported that CSCs have more
resistance to barren microenvironment [4]. Our data of
CCK8 assay suggested that CD271+ SaoS2 cells had
higher cell viability than CD271- SaoS2 cells under LH
culture condition, but inhibition of autophagy reversed
this trend (Fig. 3a). Detection of LDH release further
confirmed these data. The level of LDH release in
CD271+ SaoS2 cells was more than that in CD271-
Fig. 1 CD271+ OS cells have higher autophagy level than CD271- OS cells under LH condition. a CD271+ and CD271- OS cells were separated
by MACS. Then, the percentage of CD271+ cells in the indicated OS cells was detected with FACS assay. The data are shown as the mean ± S.D.
(n = 3; **, P < 0.01). b The mRNA expression of autophagy-relative genes in the CD271- and CD271+ SaoS2 cells under normal and LH conditions
at 24 h was examined with qPCR. The data are shown as the mean ± S.D. (n = 3; **, P < 0.01). c The protein level of LC3 and p62 in the indicated
OS cells under normal and LH conditions at 24 h was detected by western blotting. d The GFP-LC3-transfected OS cells under normal and LH
conditions at 24 h were captured with a fluorescence microscope. The mean number of GFP-LC3 dots per the indicated OS cells from three
replicates are shown as the mean ± S.D. (**, P < 0.01)
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SaoS2 cells under LH condition. And autophagy defects
lead to increased LDH release both in CD271+ and
CD271- SaoS2 cells. Moreover, there was not any notice-
able difference in LDH release level between autophagy-
deficient CD271+ and CD271- SaoS2 cells (Fig. 3b). De-
tections of another two cell death evaluation assays,
caspase-3 activity and flow cytometry analysis using
Annexin V/PI double staining, obtained similar results
(Fig. 3c and d). FACS analysis also suggested that LH
treatment resulted in the increase of percentage of
CD271+ cells in SaoS2 cells, but autophagy deficiency
reversed this increase (Fig. 3e). We further verified these
Fig. 2 Autophagy-deficiency has no significant influence on basic biological activities in OS cells under normal condition. a–i The indicated OS
cells were cultured in normal condition. a, f The protein level of Atg5 and Atg7 in the transfected SaoS2 (a) and MNNG/HOS (f) cells was
detected by western blotting. b, g The percentage of CD271+ cells in the transfected SaoS2 (b) and MNNG/HOS (g) cells were examined with
FACS assay. The data are shown as the mean ± S.D. (n = 3). c The cell viability of the indicated SaoS2 cells was detected with CCK8 assay at the
indicated time points. The data are shown as the mean ± S.D. (n = 3). d, h The indicated SaoS2 cells were stained with BrdU and images were
captured with a fluorescence microscope. The percentage of Brdu + cells in the indicated SaoS2 (d) and MNNG/HOS (H) cells was shown in
graphs. The data from three replicates are shown as the mean ± S.D. e, i The cell death of the indicated SaoS2 (e) and MNNG/HOS (i) cells was
analyzed by Annexin-V-FITC/PI double staining with FACS. The percentage of dead cells (Annexin-V-positive or PI-positive) was shown in graph.
The data from three replicates are shown as the mean ± S.D
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Fig. 3 Autophagy-deficiency reduces the advantages of CD271+ OS cells in terms of resistance to LH condition. a–h The indicated OS cells were cultured
in LH condition. a, f The cell viability of the indicated SaoS2 (a) and MNNG/HOS (f) cells was detected by CCK8 assay at the indicated time points. The data
are shown as the mean ± S.D. (n= 3; *, P< 0.05; **, P< 0.01). b, g The LDH release level of the indicated SaoS2 (b) and MNNG/HOS (g) cells under LH
treatment was detected at 24 h. The data are shown as the mean ± S.D. (n= 3; *, P< 0.05; **, P< 0.01). c The caspase-3 activity of the indicated SaoS2 cells
under LH treatment was detected at 24 h. The data are shown as the mean ± S.D. (n= 3; *, P< 0.05; **, P< 0.01). d, h The cell death of the indicated SaoS2
(d) and MNNG/HOS (H) cells under LH treatment was analyzed by Annexin-V-FITC/PI double staining with FACS. The percentage of dead cells (Annexin-V-
positive or PI-positive) was shown in graph. The data from three replicates are shown as the mean ± S.D. e The percentage of CD271+ cells in the
transfected SaoS2 cells under LH treatment at the indicated times was examined with FACS assay. The data are shown as the mean ± S.D. (n = 3)
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results in MNNG/HOS cells (Fig. 3f–h). These data
demonstrated that autophagy-deficient CD271+ OS cells
lost the advantage of tolerance to LH condition.
Autophagy deficiency results in the elimination of the
advantage of drug resistance in CD271+ OS cells
Drug resistance of CSCs is considered an important cause
resulting in chemotherapy- resistant and recurrence of
tumor. We used Cisplatin of different concentration to treat
CD271+ and CD271- OS cells for 48 h. The results
revealed that CD271+ OS cells had a higher IC50, an indi-
cator of drug resistance, to Cisplatin compared with
CD271- OS cells. Autophagy deficiency increased substan-
tially IC50 to Cisplatin both in CD271+ and CD271- OS
cells. Importantly, autophagy-deficient CD271+ OS cells
had an approximate IC50 to Cisplatin with autophagy-
deficient CD271- OS cells (Fig. 4a and Additional file 1A).
In the Epirubicin treatment, we observed similar results
Fig. 4 Autophagy-deficiency eliminates the advantages of CD271+ OS cells in terms of resistance to chemotherapeutics. a, b The indicated SaoS2
and MNNG/HOS cells were treated with Cisplatin or Epicubicin of different doses for 48 h, and IC50 of the indicated OS cells to Cisplatin (a) or
Epicubicin (b) were evaluated by CCK8. The data are shown as the mean ± S.D. (n = 3; **, P < 0.01). c The LDH release level of the indicated SaoS2
and MNNG/HOS cells was detected at 24 h after Cisplatin (4 μg/ml) treatment. The data are shown as the mean ± S.D. (n = 3; *, P < 0.05; **,
P < 0.01). d The caspase-3 activity of the indicated SaoS2 and MNNG/HOS cells was detected at 24 h after Epirubicin (2 μg/ml) treatment.
The data are shown as the mean ± S.D. (n = 3; *, P < 0.05; **, P < 0.01). e, f FACS assay detected the percentage of CD271+ cells in the
indicated SaoS2 and MNNG/HOS cells at 24 h after Cisplatin (4 μg/ml, e) or Epirubicin (2 μg/ml, f) treatment. The data are shown as the
mean ± S.D. (n = 3; *, P < 0.05; **, P < 0.01)
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(Fig. 4b and Additional file 1B). Detections of LDH release
and caspase-3 activity also showed that autophagy defi-
ciency resulted in the disappearance of superiority of drug
resistance in CD271+ OS cells (Fig. 4c and d). After Cis-
platin or Epirubicin treatment, higher drug resistance of
CD271+ OS cells led to increased percentage of CD271+
cells, but inhibition of autophagy reversed this trend (Fig. 4e
and f). The results above demonstrated that autophagy de-
ficiency brought about the elimination of advantage of drug
resistance in CD271+ OS cells.
Defective autophagy leads to the loss of superiority of
tumorigenicity in CD271+ OS cells
CSCs have the advantage of tumorigenicity in vitro and
vivo compared to non-CSCs. We next detected the influ-
ence of autophagy deficiency on tumorigenicity of
CD271+ OS cells. Colony formation assay showed that
CD271+ SaoS2 cells had more colony formation than
CD271- SaoS2 cells. And autophagy deficiency reduced
colony formation ability both in CD271+ and CD271-
SaoS2 cells. Moreover, there was no remarkable differ-
ence in colony formation ability between autophagy-
deficient CD271+ and CD271- SaoS2 cells (Fig. 5a). In
Fig. 2, our results showed that autophagy deficiency had
no obvious impact on cell proliferation and death of
CD271+ OS cells. Therefore, the result of Fig. 5a sug-
gested that autophagy deficiency declined significantly
tumorigenicity in vitro of CD271+ SaoS2 cells. To
further confirm this finding, we also utilized tumor
sphere formation assay. The results showed that CD271
+ SaoS2 cells had more sphere formation and larger
sphere volume compared to CD271- SaoS2, but autoph-
agy deficiency reversed this trend (Fig. 5b). Meanwhile,
we observed similar consequences in MNNG/HOS cells
(Fig. 5c and d). Moreover, autophagy deficiency de-
creased the protein level of stemness factors Nanog,
Oct3/4 and p-Stat3 [10, 26] in CD271+ OS cells to the
comparable level in CD271- OS cells (Fig. 5e).
We further examined the influence of autophagy in-
hibition on tumorigenicity in vivo of CD271+ cells. We
observed that autophagy inhibition resulted in the elim-
ination of advantage of tumor growth in CD271+ OS
cells (Fig. 6a). The results revealed that just 1 × 106
CD271+ cells were large enough to form a tumor, but
tumor incidence of 1 × 107 CD271- cells only was three-
fifths. Tumor incidence of 1 × 107 Atg5-deficient CD271
+ cells was reduced to one-fifths. CQ treatment was also
decreased tumor incidence of CD271+ cells. Autophagy-
inhibited CD271+ cells had similar tumor incidence with
autophagy-inhibited CD271- cells (Table 1). Additionally,
both in the tumors originated from CD271+ and
CD271- OS cells, autophagy inhibition had no obvious
influence on the tumor tissue morphology (Fig. 6b). All
data above demonstrated that autophagy inhibition re-
sulted in the loss of superiority of tumorigenicity in
CD271+ OS cells.
Fig. 5 Autophagy-deficiency decreases the advantage of CD271+ OS cells in terms of tumorigenesis in vitro. a–d The colony-forming and
sphere-forming abilities of the indicated SaoS2 (a, b) and MNNG/HOS (c, d) cells were detected. The mean number of colonies (a, c) and spheres
(b, d) per well and the mean volume of spheres in the indicated groups are shown in graphs. The data from three replicates are shown as the
mean ± S.D. e The protein expression of Nanog, Oct3/4, Stat3 and p-Stat3 in the indicated OS cells were examined by western blotting
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Discussion
In this study, we found that CD271+ OS CSCs had a
similar basic autophagy level with CD271- OS cells, but
CD271+ cells had a higher autophagy activity than
CD271- cells under LH condition. Autophagy deficiency
had no prominent effects on cell proliferation and death
both in CD271+ and CD271- OS cells. However, stem-
ness of CD271+ OS cells was significantly fell by inhibit-
ing autophagy. CD271+ OS cells had numerous
advantages, including resistances to LH condition and
chemotherapeutics and tumorigenicity, compared to
CD271- OS cells. Autophagy deficiency obviously sup-
pressed the three characteristics of CD271+ OS cells.
Autophagy-deficient CD271+ OS cells had no remark-
able difference with autophagy-deficient CD271- OS
cells in these three stemness-associated respects. These
findings suggest that autophagy contributes to the stem-
ness of CD271+ OS cells.
Previous studies demonstrated that autophagy is a pro-
tective mechanism of OS cells. Huang J, et al. found that
HMGB1 increased drug resistance of OS cells by indu-
cing autophagy [27]. Shimizu T and his colleagues also
reported that IGF2-induced autophagy decreased che-
motherapeutic sensitivity in OS cells [28]. Autophagy in-
duced by PERK, an ubiquitously-expressed endoplasmic
reticulum (ER) protein kinase, contributed to the resist-
ance to ER stress-induced apoptosis in OS cells [29].
Both hypoxia and nutrient deficiency induced reactive
oxygen species (ROS) production [30]. The research of
Liu Y, et al. suggested that DSTD, an androstenedione
derivative, induced ROS-mediated autophagy. And au-
tophagy inhibition promoted cell death by DSTD treat-
ment [31]. In addition, the study of Akin D, et al. reveal
Fig. 6 Autophagy inhibition restricts the advantage of CD271+ OS cells in terms of tumorigenesis in vivo. a Growth curve of tumor originated
from 107 indicated MNNG/HOS cells in 6 weeks (left panel). Tumor volumes of the indicated groups at 6 weeks are shown at the right panel. The
data are shown as the mean ± S.D. (n = 5; **, P < 0.01). b Representative H&E staining images in tumors originated from 107 indicated MNNG/HOS
cells at 6 weeks. Magnification, 200×. Bar, 100 μm
Table 1 Tumor incidence of CD271+ or CD271- transfected
MNNG/HOS cells in vivo
Cell number (per 100 μl) 1 × 105 1 × 106 1 × 107
CD271 + (Scr-shRNA) 2/5 4/5 5/5
CD271 + (Atg5-shRNA) 0/4 0/5 1/5
CD271 + (CQ) 0/4 0/5 2/5
CD271-(Scr-shRNA) 0/4 0/4 3/5
CD271-(Atg5-shRNA) 0/4 0/4 1/5
CD271-(CQ) 0/4 0/4 1/5
MNNG/HOS cells were injected subcutaneously into the oxter of left forelimb
of BALB/c-Nude mice. Numbers indicate tumor bearing/injected mice
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that suppression of autophagy by an ATG4B antagonist
reduced the development of SaoS-2 OS tumors in vivo
[32]. These studies are in accord with our findings that
autophagy deficiency increased the sensitivity to LH
condition and chemotherapy drugs and reduced tumori-
genesis both in CD271+ and CD271- OS cells. And our
findings indicated that autophagy plays a crucial role in
these aspects of OS cells because there is no significant
difference in these aspects in autophagy-deficient CD271
+ and CD271- cells. Notably, some earlier studies
showed that autophagy increases the sensitivity to che-
motherapeutics in OS cells by autophgic death. For ex-
ample, Meschini S, et al. reported that bisindolic alkaloid
voacamine induced autophagy was effective against drug
resistance tumor cells in vitro [33]. These research hints
that the influence of autophagy inhibition on drug resist-
ance of OS cells has complexity and may involve the
drug specificity for autophagy and overall influences of
autophagic protection and autophagic death.
Compared with non-CSCs, CSCs have higher autoph-
agy level in breast cancer [13], pancreatic ductal adeno-
carcinoma [15], hepatoma [19] and bladder cancer [20],
but lower autophagy level in glioblastoma [21]. In our
study, we found that CD271+ OS CSCs had similar basic
autophagy level and higher autophagy activity compared
to CD271- OS cells. Meanwhile, numerous researches
investigated the influence of autophagy on CSCs. Two
research teams found that autophagy contributes to
maintenance of CD44 + CD24-/low CSCs and ALDH+
CSCs [12–14]. Research on pancreatic ductal adenocar-
cinoma revealed that moderate autophagy helped CSCs
survival under hypoxia starvation condition, but both
autophagy inhibition and excess autophagy resulted in
killing CSCs [15]. Research of Wei Lixin team demon-
strated that autophagy played a major role in the
survival of liver CSCs under hypoxia starvation micro-
environment [19]. Yang Hao-Zheng, et al. reported that
autophagy enhanced chemoresistance of colorectal CSCs
[18]. However, Stephen Doxsey and his colleagues re-
ported that autophagy inhibition promoted malignant
transformation of stem cells by inducing midbody accu-
mulation [34]. And two studies showed that autophagy
contributes to drug-induced decrease of CSCs [24, 25].
The different role of autophagy on CSCs is possibly due
to various kinds of cancers and specific impact factors.
Additionally, our results revealed that autophagy defi-
ciency decreases stemness of CD271+ OS cells, but have
no prominent influence on percentage of CD271+ OS
cells. This finding hints CD271+ OS cells may have a
cell subpopulation which has more features of CSCs.
Conclusion
In summary, our results indicated that CD271+ OS
CSCs had higher autophagy activity than CD271- OS
cells under stress condition. And autophagy contributes
to the stemness of CD271+ OS CSCs. Autophagy-
deficient CD271+ OS CSCs disappeared the advantages
in terms of tolerance to LH condition, drug resistance
and tumorigenicity in vitro and vivo compared to
CD271- OS cells.
Additional file
Additional file 1: Cell viaiblities of OS cells after chemotherapeutics
treatments. (A, B) The indicated SaoS2 and MNNG/HOS cells were treated
with Cisplatin (A) or Epicubicin (B) of different doses for 48 h. Then, the
cell viability of the indicated cells was detected by CCK8 assay. The data
are showen as the mean ± S.D. (n = 3). (PPTX 232 kb)
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